Egetis Therapeutics AB stock analysis
Egetis Therapeutics AB (0ABW) Share Price & Analysis
0ABW Stock Chart & Stats
- Day’s Range
- SEK 11.12 - SEK 11.14
- 52-Week Range
- SEK 4.04 - SEK 11.18
- Previous Close
- SEK 11.14
- Volume
- N/A
- Average Volume (3M)
- 2.74M
- Market Cap
- SEK 5.17B
- Enterprise Value
- SEK 3.93B
- Total Cash (Recent Filing)
- SEK 266.50M
- Total Debt (Recent Filing)
- SEK 73.90M
- Price to Earnings (P/E)
- ―
- Beta
- -0.83
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- -0.11
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
The stronger trailing revenue base indicates improving commercial traction and broader product adoption. If this growth continues, it can provide greater operating leverage and help the company spread its development and commercialization costs across a larger revenue stream over the next several quarters.
Manageable Leverage
Modest and improving leverage gives Egetis more balance-sheet flexibility than a heavily debt-funded biotech. Lower debt relative to equity can reduce near-term financing pressure and preserve capacity to support rare-disease development while revenue and profitability continue to mature.
Rare-disease Specialization
A focused orphan-drug strategy targets serious diseases where medical need is high and specialist expertise can be valuable. Late-stage development and commercialization may also shorten the path from clinical investment to potential recurring product revenue compared with earlier-stage portfolios.
Bears Say
Severe Cash Burn
Persistent and worsening cash outflows mean the business is not currently self-funding its operations or development programs. Continued reliance on external capital can dilute shareholders, increase financing sensitivity, and constrain strategic flexibility if funding conditions become less supportive.
Deep Operating Losses
Losses that greatly exceed revenue show that the current cost base remains materially above the company’s commercial scale. Unless revenue expands substantially or spending becomes more efficient, the resulting earnings deficit can persist and delay the transition to sustainable profitability.
Negative Returns And Equity Erosion
A deeply negative return on equity indicates that capital is currently producing substantial losses rather than durable shareholder returns. Continued equity erosion can weaken financial resilience over time and increase the importance of repeated external funding to maintain development and commercialization activities.
Egetis Therapeutics AB News
0ABW FAQ
What was Egetis Therapeutics AB’s price range in the past 12 months?
What is Egetis Therapeutics AB’s market cap?
When is Egetis Therapeutics AB’s upcoming earnings report date?
How were Egetis Therapeutics AB’s earnings last quarter?
Is Egetis Therapeutics AB overvalued?
Does Egetis Therapeutics AB pay dividends?
What is Egetis Therapeutics AB’s EPS estimate?
How many shares outstanding does Egetis Therapeutics AB have?
What happened to Egetis Therapeutics AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Egetis Therapeutics AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Egetis Therapeutics AB
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nicklas Westerholm
- Employees
- 61
- Website
- www.egetis.com
- Address
- Klara Norra Kyrkogata 26, Stockholm, AB, 111 22, SE
Egetis Therapeutics AB (0ABW) Earnings & Revenues
0ABW Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 4 | 5 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 11 | 0 | 1 |










